European Pharma Launches Strategy Manifesto
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
The manifesto is built on three “separate but highly interdependent pillars”:
1. Improve health outcomes & remove inequalities to better patient benefits;
2. Support sustainable & predictable healthcare systems to speed access to medicines;
3. Build a thriving innovative life sciences sector to promote European competitiveness.
It follows the launch of EFPIA’s #HealthyEU Health and Growth campaign, which outlines opportunities and threats faced by the patients and the healthcare sector.
EFPIA President, Sanofi CEO Christopher Viehbacher, highlighted how the technological, behavioural and therapeutic innovations outlined in the Manifesto should be used to rebuild sustainable healthcare systems, improve access to medicines and “do a better job at preventing and treating chronic disease”.
The research-based pharmaceutical industry employs over 700,000 people in Europe, and contributes 17% of total business enterprise R&D employment.
To view the EFPIA Maifesto, click here.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Study: GLP-1, SGLT2s Linked to Reduced Alzheimer Disease Risk in Patients with Type 2 Diabetes
April 17th 2025A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease compared to other glucose-lowering drugs.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
